A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
for Hidradenitis Suppurativa
2 locations incl. Sacramento
Sponsor: AbbVie
Sex: All·Age: 18 - 75
Code: NCT06524635·Phase 2·Recruiting·Listed Jul 2024